The technologies of genetic engineering in treatment of chronic lower limb ischemia

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 9-10, 2006, Pages 6-11

  Bochkov, N P ^a   Konstantinov, B A ^a   Gavrilenko, A V ^a   Voronov, D A ^a   Avdeyeva, S V ^a   Khaydarova, N V ^a   Tarantul, V Z ^a   Sverdlov, Ye D ^a   Naroditsky, B S ^a   Gintsburg, A L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751570633     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Baumgartner I., Pieczek A., Manor O. et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 31: 1114-1122.
2. Baumgartner I. Therapeutic angiogenesis: theoretic problems using vascular endothelial growth factor. Curr. Cardiol. Rep. 2000; 2 (1): 24-28.
3. Marti H. H., Risau W. Angiogenesis in ischemic disease. Thromb. Haemost. 1999; 82 (suppl. 1): 44-52.
4. Nikol S., Huehns T. Y. Preclinical and clinical experience in vascular gene therapy: advantages over conservative/standard therapy. J. Invasive Cardiol. 2001; 13 (4): 333-338.
5. Yia-Hertulla S., Martin J. Cardiovascular gene therapy. Lancet 2000; 355: 213-222.
6. Folkman J. Angiogenesis and its inhibitors. In: Hellman S., Rosenberg S. Important advances in oncology. Philadelphia: JB Lippincott; 1985. 42-62.
7. Folkman J. Angiogenic therapy of the human heart. Circulation 1998; 97: 628-629.
8. Folkman J. Therapeutic angiogenesis in ischemic limbs. Circulation 1998; 97: 1108-1110.
9. Griffoen A., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000; 52 (2): 237-268.
10. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J. Vasc. Surg. 2003; 38 (1): 198-203.
11. Collinson D., Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur. J. Vasc. Endovasc. Surg. 2004; 28: 9-23.
12. Bruick R., McKnight S. Building better vasculature. Genes and Dev. 2001; 15 (19): 2497-2502.
13. PAMH 2004; 9: 48-55.
14. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 1999; 77 (7): 527-543.
15. Kipshidze N., Chekanov V., Chawla P. et al. Angiogenesis in a patient with ischemic limb induced by intramuscular injection of vascular endothelial growth factor and fibrin platform. Tex. Heart Inst. J. 2000; 27 (2): 196-200.
16. Rajagopalan S., Mohler E., Lederman R. et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease; a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933.
17. Timar J., Dome B., Fazekas K. et al. Angiogenesis-dependent diseases and angiogenesis therapy. Pathol. Oncol. Res. 2001; 7 (2): 85-94.
18. Zachary I., Mathur A. Vascular protection a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1512.
19. Poltorak Z., Cohen T., Neufeld G. The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. Herz 2000; 25 (2): 126-129.
20. Masaki I., Yonemitsu Y. Angiogenic gene therapy for experimental critical limb ischemia. Circ. Res. 2002; 90: 966.
21. Soeki T., Tamura Y., Shinohara H. Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart and Vessels 2000; 15: 105-111.
22. Mohler E. R., Rajagopalan S., Olin J. W. et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. Vasc. Med. 2003; 8 (1): 9-13.
23. Perletti G., Marras E., Dondi D. et al. Assessment of the biological activity of an improved naked-DNA vector for angiogenesis gene therapy on a novel non-mammalian model. Int. J. Mol. Med. 2003; 11 (6): 691-696.
24. Witzenbichler B., Asahara T., Murohara T. et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 1998; 153 (2): 381-394.
25. Yamauchi A., Ito Y., Morikawa M. et al. Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. J. Gene Med. 2003; 5 (11): 994-1004.
26. Isner J. M., Vale P. R., Symes J. F., Losordo D. W. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ. Res. 2001; 89 (5): 389-400.
27. Palmer-Kazen U., Wariaro D., Luo F., Wahlberg E. Vascular endothelial cell growth factor and fibroblast growth factor 2 expression in patients with critical limb ischemia. J. Vasc. Surg. 2004; 39 (3): 621-628.
28. Hirsch D., Pantely G. Therapeutic angiogenesis: just the basic fact(or)s, please. J. Am. Coll. Cardiol. 1997; 29 (5): 1107-1108.
29. Hughes S., Crossman D., Hall P. Expression of basic and acidic fibroblast growth factor and their receptor in normal and atherosclerotic human arteries. Cardiovasc. Res. 1993; 27: 1214-1219.
30. Shou M., Thirumurti V., Rajanayagam M. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels. J. Am. Coll. Cardiol. 1997; 29 (5): 1102-1106.
31. Isner J. M., Baumgartner I., Rauh G. et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg. 1998; 28 (6): 964-973; discus.: 73-75.
32. Sellke F. Gene therapy in cardiac surgery: is there a role? J. Thorac. Cardiovasc. Surg. 2003; 994-997.
33. Tuomisto T. T., Rissanen T. T., Vajanto I. et al. HIF-VRGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DMA array. Atherosclerosis 2004; 174 (1): 111-120.
34. Whitlock P. R., Hackett N. R., Leopold P. L. et al. Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol. Ther. 2004; 9 (1): 67-75.